2024-07-08 10:53:56 ET
Summary
- Pfizer's recent financial performance and Wall Street analysts' expectations around the upcoming quarterly earnings release suggest that we are currently at an inflection point.
- The company's current pipeline of new product developments looks promising, and two recent FDA approvals underscore its ability to deliver new products to the market.
- I expect more full-year EPS guidance upgrades soon, as it appears that the company is moving ahead of management's initial cost-cutting plans.
- My valuation suggests there is a 30% upside potential even if no real dividend growth is incorporated into the DDM model.
Investment thesis
My previous bullish thesis about Pfizer Inc. ( PFE ) aged well because the stock returned 8.1% to investors since April, outperforming the broader U.S. market....
Read the full article on Seeking Alpha
For further details see:
Pfizer: The Inflection Point Is Here